Logo image of IRMD

IRADIMED CORP (IRMD) Stock Fundamental Analysis

NASDAQ:IRMD - Nasdaq - US46266A1097 - Common Stock - Currency: USD

62.67  +1.44 (+2.35%)

After market: 62.67 0 (0%)

Fundamental Rating

8

Overall IRMD gets a fundamental rating of 8 out of 10. We evaluated IRMD against 191 industry peers in the Health Care Equipment & Supplies industry. IRMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IRMD is growing strongly while it is still valued neutral. This is a good combination! This makes IRMD very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

In the past year IRMD was profitable.
In the past year IRMD had a positive cash flow from operations.
IRMD had positive earnings in each of the past 5 years.
IRMD had a positive operating cash flow in each of the past 5 years.
IRMD Yearly Net Income VS EBIT VS OCF VS FCFIRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M 10M 15M 20M

1.2 Ratios

IRMD has a better Return On Assets (19.76%) than 97.89% of its industry peers.
IRMD's Return On Equity of 22.33% is amongst the best of the industry. IRMD outperforms 95.79% of its industry peers.
IRMD has a Return On Invested Capital of 19.59%. This is amongst the best in the industry. IRMD outperforms 98.42% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 8.15%.
The 3 year average ROIC (15.74%) for IRMD is below the current ROIC(19.59%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 19.76%
ROE 22.33%
ROIC 19.59%
ROA(3y)14.97%
ROA(5y)12.26%
ROE(3y)18.14%
ROE(5y)14.8%
ROIC(3y)15.74%
ROIC(5y)N/A
IRMD Yearly ROA, ROE, ROICIRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 10 15 20 25

1.3 Margins

IRMD's Profit Margin of 26.12% is amongst the best of the industry. IRMD outperforms 95.79% of its industry peers.
IRMD's Profit Margin has improved in the last couple of years.
The Operating Margin of IRMD (29.91%) is better than 97.37% of its industry peers.
IRMD's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 77.14%, IRMD belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
IRMD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 29.91%
PM (TTM) 26.12%
GM 77.14%
OM growth 3YN/A
OM growth 5Y9.17%
PM growth 3Y82.43%
PM growth 5Y4.85%
GM growth 3Y0.98%
GM growth 5Y0.05%
IRMD Yearly Profit, Operating, Gross MarginsIRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRMD is creating value.
Compared to 1 year ago, IRMD has more shares outstanding
Compared to 5 years ago, IRMD has more shares outstanding
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IRMD Yearly Shares OutstandingIRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
IRMD Yearly Total Debt VS Total AssetsIRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

IRMD has an Altman-Z score of 46.18. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 46.18, IRMD belongs to the best of the industry, outperforming 97.89% of the companies in the same industry.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 46.18
ROIC/WACC2.14
WACC9.16%
IRMD Yearly LT Debt VS Equity VS FCFIRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.3 Liquidity

IRMD has a Current Ratio of 9.21. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
IRMD's Current ratio of 9.21 is amongst the best of the industry. IRMD outperforms 91.58% of its industry peers.
A Quick Ratio of 7.82 indicates that IRMD has no problem at all paying its short term obligations.
IRMD's Quick ratio of 7.82 is amongst the best of the industry. IRMD outperforms 91.58% of its industry peers.
Industry RankSector Rank
Current Ratio 9.21
Quick Ratio 7.82
IRMD Yearly Current Assets VS Current LiabilitesIRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.48%, which is quite good.
IRMD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.34% yearly.
The Revenue has grown by 13.24% in the past year. This is quite good.
The Revenue has been growing by 16.58% on average over the past years. This is quite good.
EPS 1Y (TTM)13.48%
EPS 3Y53.4%
EPS 5Y22.34%
EPS Q2Q%0%
Revenue 1Y (TTM)13.24%
Revenue growth 3Y27.38%
Revenue growth 5Y16.58%
Sales Q2Q%11.03%

3.2 Future

Based on estimates for the next years, IRMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.01% on average per year.
IRMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.79% yearly.
EPS Next Y14.41%
EPS Next 2Y9.82%
EPS Next 3Y14.01%
EPS Next 5YN/A
Revenue Next Year11.59%
Revenue Next 2Y11.02%
Revenue Next 3Y14.79%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
IRMD Yearly Revenue VS EstimatesIRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
IRMD Yearly EPS VS EstimatesIRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 39.17, the valuation of IRMD can be described as expensive.
IRMD's Price/Earnings ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 72.11% of the companies in the same industry.
IRMD's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 28.58.
The Price/Forward Earnings ratio is 35.11, which means the current valuation is very expensive for IRMD.
Based on the Price/Forward Earnings ratio, IRMD is valued a bit cheaper than the industry average as 73.16% of the companies are valued more expensively.
IRMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 95.03, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 39.17
Fwd PE 35.11
IRMD Price Earnings VS Forward Price EarningsIRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than 71.05% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IRMD is valued a bit cheaper than the industry average as 77.89% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 46.29
EV/EBITDA 32.69
IRMD Per share dataIRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
IRMD has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as IRMD's earnings are expected to grow with 14.01% in the coming years.
PEG (NY)2.72
PEG (5Y)1.75
EPS Next 2Y9.82%
EPS Next 3Y14.01%

More info and screens

2

5. Dividend

5.1 Amount

With a yearly dividend of 0.99%, IRMD is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 1.58, IRMD pays a better dividend. On top of this IRMD pays more dividend than 94.21% of the companies listed in the same industry.
With a Dividend Yield of 0.99, IRMD pays less dividend than the S&P500 average, which is at 2.28.
Industry RankSector Rank
Dividend Yield 0.99%

5.2 History

IRMD has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
IRMD Yearly Dividends per shareIRMD Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 0.5 1 1.5

5.3 Sustainability

63.24% of the earnings are spent on dividend by IRMD. This is not a sustainable payout ratio.
DP63.24%
EPS Next 2Y9.82%
EPS Next 3Y14.01%
IRMD Yearly Income VS Free CF VS DividendIRMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
IRMD Dividend Payout.IRMD Dividend Payout, showing the Payout Ratio.IRMD Dividend Payout.PayoutRetained Earnings

More info and screens

IRADIMED CORP

NASDAQ:IRMD (2/5/2025, 8:07:39 PM)

After market: 62.67 0 (0%)

62.67

+1.44 (+2.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)02-13 2025-02-13/amc
Inst Owners56.06%
Inst Owner Change-0.59%
Ins Owners37.01%
Ins Owner Change1.37%
Market Cap794.03M
Analysts82.5
Price Target66.3 (5.79%)
Short Float %1.86%
Short Ratio3.68
Dividend
Industry RankSector Rank
Dividend Yield 0.99%
Yearly Dividend1.05
Dividend Growth(5Y)N/A
DP63.24%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.16%
Min EPS beat(2)9.5%
Max EPS beat(2)12.81%
EPS beat(4)3
Avg EPS beat(4)6.01%
Min EPS beat(4)-3.61%
Max EPS beat(4)12.81%
EPS beat(8)7
Avg EPS beat(8)7.79%
EPS beat(12)11
Avg EPS beat(12)12.18%
EPS beat(16)14
Avg EPS beat(16)13.5%
Revenue beat(2)0
Avg Revenue beat(2)-0.57%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-0.42%
Min Revenue beat(4)-1.28%
Max Revenue beat(4)0.72%
Revenue beat(8)4
Avg Revenue beat(8)0.01%
Revenue beat(12)5
Avg Revenue beat(12)-0.19%
Revenue beat(16)8
Avg Revenue beat(16)1.2%
PT rev (1m)8.33%
PT rev (3m)8.33%
EPS NQ rev (1m)1.15%
EPS NQ rev (3m)3.53%
EPS NY rev (1m)0.3%
EPS NY rev (3m)6.07%
Revenue NQ rev (1m)1.06%
Revenue NQ rev (3m)-2.32%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)0.55%
Valuation
Industry RankSector Rank
PE 39.17
Fwd PE 35.11
P/S 11.14
P/FCF 46.29
P/OCF 33.71
P/B 9.52
P/tB 9.86
EV/EBITDA 32.69
EPS(TTM)1.6
EY2.55%
EPS(NY)1.79
Fwd EY2.85%
FCF(TTM)1.35
FCFY2.16%
OCF(TTM)1.86
OCFY2.97%
SpS5.63
BVpS6.59
TBVpS6.36
PEG (NY)2.72
PEG (5Y)1.75
Profitability
Industry RankSector Rank
ROA 19.76%
ROE 22.33%
ROCE 24.74%
ROIC 19.59%
ROICexc 49%
ROICexgc 53.49%
OM 29.91%
PM (TTM) 26.12%
GM 77.14%
FCFM 24.06%
ROA(3y)14.97%
ROA(5y)12.26%
ROE(3y)18.14%
ROE(5y)14.8%
ROIC(3y)15.74%
ROIC(5y)N/A
ROICexc(3y)61.12%
ROICexc(5y)N/A
ROICexgc(3y)67.67%
ROICexgc(5y)N/A
ROCE(3y)19.88%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y3.9%
ROICexc growth 3YN/A
ROICexc growth 5Y3.72%
OM growth 3YN/A
OM growth 5Y9.17%
PM growth 3Y82.43%
PM growth 5Y4.85%
GM growth 3Y0.98%
GM growth 5Y0.05%
F-Score8
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 772.64%
Cap/Sales 8.97%
Interest Coverage 250
Cash Conversion 106.32%
Profit Quality 92.1%
Current Ratio 9.21
Quick Ratio 7.82
Altman-Z 46.18
F-Score8
WACC9.16%
ROIC/WACC2.14
Cap/Depr(3y)459.84%
Cap/Depr(5y)293.36%
Cap/Sales(3y)5.84%
Cap/Sales(5y)4.16%
Profit Quality(3y)69.37%
Profit Quality(5y)137.47%
High Growth Momentum
Growth
EPS 1Y (TTM)13.48%
EPS 3Y53.4%
EPS 5Y22.34%
EPS Q2Q%0%
EPS Next Y14.41%
EPS Next 2Y9.82%
EPS Next 3Y14.01%
EPS Next 5YN/A
Revenue 1Y (TTM)13.24%
Revenue growth 3Y27.38%
Revenue growth 5Y16.58%
Sales Q2Q%11.03%
Revenue Next Year11.59%
Revenue Next 2Y11.02%
Revenue Next 3Y14.79%
Revenue Next 5YN/A
EBIT growth 1Y11.47%
EBIT growth 3YN/A
EBIT growth 5Y27.27%
EBIT Next Year6.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y95.17%
FCF growth 3Y1.76%
FCF growth 5Y-5.18%
OCF growth 1Y127.12%
OCF growth 3Y32.26%
OCF growth 5Y12.78%